Are Capisetin Tablets/Caposetinib currently sold in domestic pharmacies?

Currently, Capivasertib has just been approved by the State Food and Drug Administration for marketing in China in April 2025. Due to its short time on the market, there is no official sales channel in conventional pharmacies, hospitals or other platforms. Although the drug has been approved by regulatory agencies in many European and American countries, it can be used as a targeted treatment for some patients with breast cancer. For patients with actual drug needs, especially cancer patients with abnormalities in the PI3K/AKT/PTEN signaling pathway confirmed by testing, they can currently only obtain them through overseas drug channels.

Overseas versions are dominated by European and American original drugs, such as the USFDA-approved version, the European EMA authorized version, the Swiss production version, etc. These versions are developed by the original manufacturers, and the price is usually higher, but the quality and efficacy are authoritatively guaranteed. At the same time, some patients will also choose the relatively lower-priced Lao version of generic drugs. These drugs are usually produced legally in countries such as India or Laos. The ingredients of the drugs are the same as the original drugs and the efficacy is similar. However, their quality control and review supervision may not be as strict as the European and American versions. In the process of cross-border drug procurement, it is necessary to carefully identify the authenticity of drugs and choose formal channels for purchasing to avoid problems with counterfeit drugs, inferior drugs or illegal online sales.

In addition, capositinib has not yet been included in China's medical insurance list, which means that even if the drug is obtained through formal overseas methods, the treatment costs must be paid entirely out of the patient's own pocket, which imposes a heavy financial burden. Therefore, before actual use, it is recommended that doctors evaluate the suitability of the treatment plan and confirm the target expression status with genetic testing to improve treatment accuracy and cost-effectiveness.

Reference materials:https://www.drugs.com/mtm/capivasertib.html